Assuming (for the sake of discussion) that L is a success this company still needs to be evaluated as a single small indication as it doesn't have any major advantages in indications past ndGBM. If we just look at the competition from vaccines alone, then many other neoantigen and DC based versions are being tested in other indications and are more advanced.
Market Data 
Markets 
AI
